相似文献
1
Current perspectives on use of anti-vascular endothelial growth factor agents for retinal disorders.
Indian J Ophthalmol. 2021 Feb;69(2):209-210. doi: 10.4103/ijo.IJO_72_21.
2
Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
BMJ Open. 2019 May 28;9(5):e022031. doi: 10.1136/bmjopen-2018-022031.
3
[The revolution in the treatment of retinal diseases: anti-VEGF treatment at the Assuta Eye Institute].
Harefuah. 2015 Apr;154(4):270-3, 278.
4
Targeted pharmacotherapy of retinal diseases with ranibizumab.
Drugs Today (Barc). 2007 Aug;43(8):529-37. doi: 10.1358/dot.2007.43.8.1120868.
5
Factors associated with pain during intravitreal injection of anti-vascular endothelial growth factor.
Eye (Lond). 2018 Sep;32(9):1544-1546. doi: 10.1038/s41433-018-0126-z. Epub 2018 May 17.
6
A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific.
Ophthalmol Retina. 2019 Jan;3(1):16-26. doi: 10.1016/j.oret.2018.08.002. Epub 2018 Aug 9.
7
COMPARATIVE RISK OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION WITH BEVACIZUMAB, AFLIBERCEPT, AND RANIBIZUMAB.
Retina. 2019 Oct;39(10):2004-2011. doi: 10.1097/IAE.0000000000002351.
8
Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
Curr Pharm Des. 2019;25(2):184-189. doi: 10.2174/1381612825666190319165824.
9
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
10
Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5636-5645. doi: 10.1167/iovs.17-22431.
引用本文的文献
1
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study.
Clin Ophthalmol. 2024 Jun 24;18:1819-1828. doi: 10.2147/OPTH.S459085. eCollection 2024.
2
Efficacy, Safety and Immunogenicity of Sun's Ranibizumab Biosimilar in Neovascular Age-Related Macular Degeneration: A Phase 3, Double-Blind Comparative Study.
Ophthalmol Ther. 2024 May;13(5):1369-1382. doi: 10.1007/s40123-024-00883-5. Epub 2024 Mar 26.
3
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes - A multicentric study.
Indian J Ophthalmol. 2023 May;71(5):1979-1985. doi: 10.4103/IJO.IJO_2688_22.
4
Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence.
Clin Ophthalmol. 2023 Apr 8;17:1067-1076. doi: 10.2147/OPTH.S407219. eCollection 2023.
5
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive Review.
Ophthalmol Ther. 2021 Sep;10(3):431-443. doi: 10.1007/s40123-021-00362-1. Epub 2021 Jun 21.
6
Insurance coverage for intravitreal injections in India-The road ahead.
Indian J Ophthalmol. 2021 May;69(5):1027-1028. doi: 10.4103/ijo.IJO_738_21.
本文引用的文献
1
Immediate onset of sterile endophthalmitis with hypopyon after intravitreal Brolucizumab in a case of polypoidal choroidal vasculopathy.
Indian J Ophthalmol. 2021 Feb;69(2):469-470. doi: 10.4103/ijo.IJO_3436_20.
2
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
3
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab.
Indian J Ophthalmol. 2021 Feb;69(2):347-351. doi: 10.4103/ijo.IJO_2516_20.
4
Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab.
J Vitreoretin Dis. 2020 Jul;4(4):269-279. doi: 10.1177/2474126420930863. Epub 2020 Jul 1.
5
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab.
Ophthalmology. 2020 Oct;127(10):1345-1359. doi: 10.1016/j.ophtha.2020.04.017. Epub 2020 Apr 25.
6
HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
Ophthalmology. 2020 Jan;127(1):72-84. doi: 10.1016/j.ophtha.2019.04.017. Epub 2019 Apr 12.
7
Intravitreal Ziv-Aflibercept: Clinical Effects and Economic Impact.
Asia Pac J Ophthalmol (Phila). 2017 Nov-Dec;6(6):561-568. doi: 10.22608/APO.2017263. Epub 2017 Oct 3.
8
Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
Curr Opin Ophthalmol. 2017 Nov;28(6):636-643. doi: 10.1097/ICU.0000000000000424.
9
Counterfeit Avastin in India: Punish the Criminals, Not the Patients.
Am J Ophthalmol. 2016 Oct;170:228-231. doi: 10.1016/j.ajo.2016.05.023. Epub 2016 Jun 7.
10
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
Zotero 插件